Zimbabwe has rejected a significant American health deal worth $367m (£272m) over five years due to Washington's insistence on confidential data.
This move came to light following a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesperson has since clarified that the US was demanding access to health data for scientific study and commercial gain while refused to share the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further dialogue to secure a deal agreeable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Context
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a court suspended a similar health funding agreement following concerns were filed about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government deals to enhance openness and accountability.
According to statements, 16 African countries have so far agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data indefinitely, with no equivalent promise of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our citizens should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems already set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This system is designed to ensure that when a nation contributes its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how future co-operation might be designed in a manner that respects the sovereignty and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the government's concerns, but suggested that talks need to persist given that a large portion of the country's Aids initiatives depended on international support.
"If technical issues exist, including those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and mutually agreed protections," the group added.
This impasse underscores the continuing challenges between receiving vital foreign assistance and protecting local interests in an increasingly data-driven world.